India, May 30 -- June's FDA calendar offers plenty for investors to keep a close eye on. Among the key names are Spero Therapeutics, awaiting an FDA decision on its antibiotic for complicated urinary tract infections; Kiniksa Pharma, seeking approval for a technology transfer of the manufacturing process for Arcalyst drug substance; and Merck, pursuing the first FDA approval for its WELIREG - KEYTRUDA combination.
Read on for a detailed look at these and other companies awaiting FDA decision in June.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....